PMID- 28660480
OWN - NLM
STAT- MEDLINE
DCOM- 20180418
LR  - 20220801
IS  - 1559-0755 (Electronic)
IS  - 0257-277X (Linking)
VI  - 65
IP  - 4
DP  - 2017 Aug
TI  - Dendritic cell-based immunotherapy: a basic review and recent advances.
PG  - 798-810
LID - 10.1007/s12026-017-8931-1 [doi]
AB  - Dendritic cells (DCs) are considered a very promising arm to activate the immune 
      system in immunotherapeutic strategies against cancer. DCs are the most powerful 
      antigen-presenting cells (APCs), being highly efficient at generating robust 
      immune responses. They are also considered the center of the immune system, since 
      they provide a crucial link between both innate and adaptive immune responses. 
      Thus, DC-based cancer immunotherapy aims to take advantage of these unique 
      characteristics of DCs to better fight cancer. During the last decade, they have 
      been the subject of numerous studies intending to develop immunotherapeutic 
      strategies against cancer through vaccination. For this purpose, it is essential 
      to gain a better insight into DC immunobiology, regulation of innate and adaptive 
      immune systems, and tumor microenvironment, as well as applying the latest 
      advances in science in order to boost their enormous anti-tumor immunotherapeutic 
      potential. In this review, we will hold focus on DC immunobiology (from their 
      origin, location, and special properties and distinct subsets to the innate and 
      adaptive immunity), on the new concept of cancer immunoediting, and on the 
      knowledge given by clinical trials using DC vaccines. Finally, future 
      perspectives for this emerging field are highlighted.
FAU - Constantino, Joao
AU  - Constantino J
AD  - Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
FAU - Gomes, Celia
AU  - Gomes C
AD  - Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and 
      Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Coimbra, 
      Portugal.
AD  - CNC.IBILI, University of Coimbra, Coimbra, Portugal.
FAU - Falcao, Amilcar
AU  - Falcao A
AD  - Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
AD  - CNC.IBILI, University of Coimbra, Coimbra, Portugal.
FAU - Neves, Bruno Miguel
AU  - Neves BM
AD  - Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
AD  - CNC.IBILI, University of Coimbra, Coimbra, Portugal.
FAU - Cruz, Maria Teresa
AU  - Cruz MT
AD  - Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal. trosete@ff.uc.pt.
AD  - CNC.IBILI, University of Coimbra, Coimbra, Portugal. trosete@ff.uc.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Immunol Res
JT  - Immunologic research
JID - 8611087
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adaptive Immunity
MH  - Animals
MH  - Cancer Vaccines/*immunology
MH  - Clinical Trials as Topic
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunity, Innate
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasms/immunology/*therapy
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Cancer
OT  - Dendritic cells
OT  - Immunotherapy
OT  - Vaccines
EDAT- 2017/07/01 06:00
MHDA- 2018/04/19 06:00
CRDT- 2017/06/30 06:00
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2018/04/19 06:00 [medline]
PHST- 2017/06/30 06:00 [entrez]
AID - 10.1007/s12026-017-8931-1 [pii]
AID - 10.1007/s12026-017-8931-1 [doi]
PST - ppublish
SO  - Immunol Res. 2017 Aug;65(4):798-810. doi: 10.1007/s12026-017-8931-1.